Characterisation of Plasmodium falciparum (Malaria) therapeutic targets Half of the world’s population is at risk of infection with the mosquito-borne malaria parasite, Plasmodium falciparum. This includes those living in many countries in Australia’s neighbouring Asia Pacific region. P. falciparum malaria results in nearly 600,000 deaths each year, mainly in children under 5 years in Africa, Asia and South America. Unfortunately, resistance has developed to our most effective anti-malarial drugs, resulting in poorer treatment outcomes for clinical cases of this deadly parasite. There is an urgent need to identify novel drugs to partner with current first-line treatments to fill this looming treatment gap. In addition, development of an effective vaccine would reduce the burden of disease and greatly facilitate efforts to eradicate malaria. Unfortunately, a highly effective vaccine to protect against malaria has not been developed to date and efforts to identify the best vaccine targets are ongoing. Our laboratory seeks to identify and characterise novel parasite proteins for their suitability as both drug and vaccine targets. We focus on invasion of the human red blood cell by the small invasive merozoite stage of the parasite lifecycle as a therapeutic target. By developing therapeutics that inhibit merozoite invasion of the red blood cell we can instantly disrupt the lifecycle of the parasite in the stage that causes all the symptoms of the disease. Two main areas of interest are available for you to explore in the laboratory. 1) Identification of novel drug-like inhibitors of merozoite invasion. This project applies a ground-breaking method for the purification of malaria merozoites, a technique developed by Boyle & Wilson et al., (PNAS, 2010), for the characterisation of invasion proteins and their inhibitors (Wilson et al. BMC Biology 2015; Wilson et al. Anti-Microbial Agents and Chemotherapy, 2013; Riglar and Richard et al., Cell Host and Microbe, 2011). Using the merozoite purification technique and flow cytometry based methods to measure invasion inhibition, you will screen a library of antimalarial compounds and identify novel inhibitors of merozoite invasion. The activity of lead inhibitors will then be defined in detail, including characterisation of inhibitory phenotypes using flow cytometry, fluorescence microscopy and genetic manipulation of potential drug targets. This project could be the starting point for the development of novel drugs to treat malaria. 2) Characterisation of the function of poorly defined proteins in invasion. The function of nearly 50% of the genes in P. falciparum parasites is poorly described or not known altogether. Malaria proteins involved in invasion are no exception with a large number of potential vaccine targets having no known function. We have developed a number of transgenic parasite lines to examine the potential role of some of these proteins in invasion and parasite growth. Using fluorescence microscopy, flow cytometry, genetic manipulation and proteomic techniques, you will characterise the proteins role in merozoite invasion of the host red blood cell and parasite growth, determine its localisation and explore potential protein binding partners. This project will uncover the role of poorly characterised proteins in invasion, allowing a thorough assessment of their suitability as therapeutic targets. During the course of the year, both projects may give you the opportunity to become familiar with: i) ii) iii) iv) v) culture of malaria parasites and purification of their lifecycle stages (in particular the invasive merozoite stage) design, cloning and transfection of malaria transfection vectors immunofluorescence microscopy leading to localization of proteins standard molecular biology and protein characterization techniques and proteomic analysis of protein binding partners Expressions of interest should be directed to Dr. Danny Wilson danny.wilson@adelaide.edu.au